Every 10-Q that Climb Bio, Inc. (CLYM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CLYM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLYM filings page.
Climb Bio, Inc. is a clinical-stage biotech developing budoprutug and CLYM116 for immune‑mediated diseases. For the quarter ended June 30, 2026 it reported a net loss of $13.5 million, wider than $8.7 million a year earlier, driven mainly by higher research and development and general and administrative expenses.
For the first six months of 2026, the net loss was $27.2 million versus $29.4 million in 2025 as prior‑year spending included a $9.0 million upfront CLYM116 license payment. Cash, cash equivalents and marketable securities totaled $239.2 million, including $103.4 million of net proceeds from an April 2026 private placement, which the company expects will fund operations into the second half of 2028.
The pipeline advanced with ongoing Phase 2 development of budoprutug in primary membranous nephropathy, Phase 1b/2a trials in immune thrombocytopenia and systemic lupus erythematosus, and a subcutaneous formulation showing robust B‑cell depletion in Phase 1. CLYM116 completed Phase 1 dosing in healthy volunteers, with pharmacokinetic and pharmacodynamic data expected in late 2026, while multiple partnered and in‑licensed programs carry substantial future milestone and royalty obligations.
Climb Bio, Inc. reported a net loss of $13.7 million for the quarter ended March 31, 2026, narrower than the $20.8 million loss a year earlier, as research and development spending declined to $9.4 million from $17.3 million.
The company ended the quarter with $146.3 million in cash, cash equivalents and marketable securities, which it currently expects to fund operations into 2028. In April 2026, Climb Bio raised about $110 million in a private placement to further support its immune‑mediated disease pipeline, including lead programs budoprutug and CLYM116.
Climb Bio (CLYM) reported third-quarter results marked by higher R&D investment and a solid liquidity position. Q3 net loss was $12.9 million, driven by research and development of $9.1 million and general and administrative of $5.8 million. For the nine months, net loss was $42.3 million.
Cash, cash equivalents and marketable securities were $175.8 million as of September 30, 2025, with stockholders’ equity of $177.0 million. Operating cash use was $38.7 million year to date. The company established an at‑the‑market program for up to $22.4 million and did not sell shares during the quarter. Shares outstanding were 68,184,435 as of October 31, 2025.
Pipeline progress included FDA clearance for a Phase 2 pMN study of budoprutug and an open‑label Phase 1b/2a study in ITP, with sites being activated and patients being enrolled and dosed. Climb also recorded a $9.0 million upfront expense earlier in the year for the CLYM116 license and noted milestone frameworks with Acelyrin, CRH and ProBioGen tied to future development and sales events.